REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer
Open Access
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 161 (2) , 374-381
Abstract
No abstract availableKeywords
Funding Information
- Ovarian Cancer Research Foundation
- Cancer Australia (1050134, 1067589)
This publication has 26 references indexed in Scilit:
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerJournal of Clinical Oncology, 2012
- Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measuresWorld Journal of Gastrointestinal Surgery, 2012
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?The Oncologist, 2009
- Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous CancerJournal of Clinical Oncology, 2007
- Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignanciesClinical Therapeutics, 2006
- The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinomaGynecologic Oncology, 2006
- Accumulation of Selected Carotenoids, α-Tocopherol and Retinol in Human Ovarian Carcinoma Ascitic FluidAnnals of Nutrition and Metabolism, 2004
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993